Investigation of EGFR/pi3k/Akt signaling pathway in seminomas

References

• Adjei AA. 2001. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 93:1062–1074.
   PubMed Web of Science ®Google Scholar
• Ahmad F, Surve P, Natarajan S, Patil A, Pol S, Patole K, Das BR. 2020. Aberrant epigenetic inactivation of RASSF1A and MGMT gene and genetic mutations of KRAS, cKIT and BRAF in Indian testicular germ cell tumours. Cancer Genet. 241:42–50.
   PubMed Web of Science ®Google Scholar
• Bos JL. 1989. Ras oncogenes in human cancer: a review. Cancer Res. 49:4682–4689.
   PubMed Web of Science ®Google Scholar
• Cardoso HJ, Figueira MI, Socorro S. 2017. The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer. J Cell Commun Sign. 11:297–307.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu J, Xia L, Xue D, Yu X, Shen D, Xu L, Li G. 2018. Testicular orphan receptor 4 promotes tumor progression and implies poor survival through AKT3 regulation in seminoma. Cancer Sci. 109:384–394.
   PubMed Web of Science ®Google Scholar
• Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. 2008. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 8:142–156.
   PubMed Web of Science ®Google Scholar
• Ehrenreiter K, Piazzolla D, Velamoor V, Sobczak I, Small JV, Takeda J, Leung T, Baccarini M. 2005. Raf-1 regulates Rho signaling and cell migration. J Cell Biol. 168:955–964.
   PubMed Web of Science ®Google Scholar
• Gan Y, Wang Y, Tan Z, Zhou J, Kitazawa R, Jiang X, Tang Y, Yang J. 2016. TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling pathway and mitochondria-mediated apoptotic pathway. Cancer Biol Ther. 17:741–750.
   PubMed Web of Science ®Google Scholar
• Garner MJ, Turner MC, Ghadirian P, Krewski D. 2005. Epidemiology of testicular cancer: an overview. Int J Cancer. 116:331–339.
   PubMed Web of Science ®Google Scholar
• Guerra F, Rocher AE, Villacorta Hidalgo J, Díaz L, Vighi S, Cardinal L, Tatti S, Cúneo N, Prat Gay G, Camporeale G, Palaoro LA. 2014. Argentophilic nucleolus organizer region as a proliferation marker in cervical intraepithelial neoplasia grade 1 of the uterine cervix. J Obst Gyn Res. 40:1717–1724.
   PubMed Web of Science ®Google Scholar
• Guerra F, Rocher AE, Angeleri A, Avagnina MA, Díaz LB, Jufé L, Mendeluk G, Palaoro L. 2016. Activation of epidermal growth factor receptor (pEGFR) and expression of argentophilic nucleolus organizer regions (AgNOR) in seminomas. Br J Med Med Res. 13:1–9.
   Google Scholar
• Hung L-Y, Tseng JT, Lee Y-C, Xia W, Wang YN, Wu ML, Chuang YH, Lai CH, Chang WC. 2008. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating aurora-A gene expression. Nucl Acids Res. 36:4337–4351.
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 5: 341–354. Erratum in: Nat Rev Cancer. 5:580, 2005.
   PubMed Web of Science ®Google Scholar
• Juliachs M, Munoz C, Moutinho CA, Vidal A, Condom E, Esteller M, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F. 2014. The PDGFRbeta-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res. 20:658–667.
   PubMed Web of Science ®Google Scholar
• Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC. 2004. KIT mutations are common in testicular seminomas. Am J Pathol. 164:305–313.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. 2007. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284.
   PubMed Web of Science ®Google Scholar
• McIntyre A, Summersgill B, Spendlove HE, Huddart R, Houlston R, Shipley J. 2005a. Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. Neoplasia. 7:1047–1052.
   PubMed Web of Science ®Google Scholar
• McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J. 2005b. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 65:8085–8089.
   PubMed Web of Science ®Google Scholar
• Miyai K, Yamamoto S, Asano T, Tamai S, Matsubara O, Tsuda H. 2010. Protein overexpression and gene amplification of epidermal growth factor receptor in adult testicular germ cell tumors: potential role in tumor progression. Cancer Sci. 101:1970–1976.
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Schiavo R, Carminati O, Sorensen BS, Gambacorta M, Siena S. 2001. Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors. Clin Cancer Res. 7:2770–2775.
   PubMed Web of Science ®Google Scholar
• Oosterhuis JW, Castedo SM, de Jong B. 1990. Cytogenetics, ploidy and differentiation of human testicular, ovarian and extragonadal germ cell tumours. Cancer Surv. 9:320–332.
   PubMedGoogle Scholar
• Paiva J, Damjanov I, Lange PH, Harris H. 1983. Immunohistochemical localization of placental-like alkaline phosphatase in testis and germ-cell tumors using monoclonal antibodies. Am J Pathol. 111:156–165.
   PubMed Web of Science ®Google Scholar
• Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, Meshinchi S. 2010. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 115:2372–2379.
   PubMed Web of Science ®Google Scholar
• Rajpert–D Meyts E. 2006. Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update. 12:303–323.
   PubMed Web of Science ®Google Scholar
• Rapley EA, Hockley S, Warren W, Johnson L, Huddart R, Crockford G, Forman D, Leahy MG, Oliver DT, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Heidenreich A, Geczi L, Bodrogi I, Olah E, Ormiston WJ, Daly PA, Looijenga LH, Guilford P, Aass N, Fosså SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, Einhorn L, Weber BL, McMaster M, Greene MH, Bishop DT, Easton D, Stratton MR. 2004. Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer. 90:2397–2401.
   PubMed Web of Science ®Google Scholar
• Sakuma Y, Sakurai S, Oguni S, Hironaka M, Saito K. 2003. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci. 94:486–491.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Esteban E, Uriol E, Zarate R, Capelan M, Muriel C, Crespo G, Berros JP, Pardo-Coto P, Perez Q, Alvarez-Fernández C, Jiménez Fonseca P, Luque M, Astudillo A. 2017. Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours. J Transl Med. 15:62–85.
   PubMed Web of Science ®Google Scholar
• Sommerer F, Hengge UR, Markwarth A, Vomschloss S, Stolzenburg JU, Wittekind C, Tannapfel A. 2005. Mutations of BRAF and RAS are rare events in germ cell tumours. Int J Cancer. 113:329–335.
   PubMed Web of Science ®Google Scholar
• Strohmeyer T, Reese D, Press M, Ackermann R, Hartmann M, Slamon D. 1995. Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J Urol. 153:511–515.
   PubMed Web of Science ®Google Scholar
• Tourne M, Radulescu C, Allory Y. 2019. Testicular germ cell tumors: histopathological and molecular features. Bull Cancer. 106:328–341.
   PubMed Web of Science ®Google Scholar
• van der Zwan YG, Biermann K, Wolffenbuttel KP, Cools M, Looijenga LH. 2015. Gonadal maldevelopment as risk factor for germ cell cancer: towards a clinical decision model. Eur Urol. 67:692–701.
   PubMed Web of Science ®Google Scholar
• Wang L, Hu H, Pan Y, Wang R, Li Y, Shen L, Yu Y, Li H, Cai D, Sun Y, Chen H. 2014. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wild type subgroup. PLoS One. 9:e88291.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gan Y, Tan Z, Zhou J, Kitazawa R, Jiang X, Tang Y, Yang J. 2016. TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathway. OncoTargets Ther. 9:409–420.
   PubMed Web of Science ®Google Scholar
• Wei J, Gan Y, Peng D, Jiang X, Kitazawa R, Xiang Y, Dai Y, Tang Y, Yang J. 2018. Long non-coding RNA H19 promotes TDRG1 expression and cisplatin resistance by sequestering miRNA-106b-5p in seminoma. Cancer Med. 7:6247–6257.
   PubMed Web of Science ®Google Scholar
• Williamson SR, Delahunt B, Magi‐Galluzzi C, Algaba F, Egevad L, Ulbright TM, Tickoo SK, Srigley JR, Epstein JI, Berney DM. 2017. Members of the ISUP Testicular Tumour Panel. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology. 70:335‐346.
   PubMed Web of Science ®Google Scholar
• Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, Wan Y. 2006. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA’s effect on cell death and migration in human ovarian cancer cells. Int J Oncol. 29:269–278.
   PubMed Web of Science ®Google Scholar
• Zhou H, Huang S. 2010. mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Exp. 20:1–16.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang Y, Guan B, Rao Q, Wang J, Ma H, Zhang Z, Zhou XC. 2014. Kit and PDGFRA gene mutations in triple negative breast cancer. Int J Clin Exp Pathol. 7:4280–4285.
   PubMed Web of Science ®Google Scholar